US 11,912,767 B2
EGFR × CD28 multispecific antibodies
Dimitris Skokos, New York, NY (US); Andrew J. Murphy, Croton-on-Hudson, NY (US); George D. Yancopoulos, Yorktown Heights, NY (US); Chia-Yang Lin, Scarsdale, NY (US); and Lauric Haber, Rye Brook, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Mar. 20, 2020, as Appl. No. 16/825,179.
Claims priority of provisional application 62/822,124, filed on Mar. 22, 2019.
Prior Publication US 2020/0299388 A1, Sep. 24, 2020
Int. Cl. C07K 16/28 (2006.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C12N 5/071 (2010.01)
CPC C07K 16/2818 (2013.01) [A61K 9/0019 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/2863 (2013.01); C12N 5/0682 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01)] 16 Claims
 
1. A bispecific antigen-binding molecule comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding domain that specifically binds human EGFR,
(a) wherein the first antigen-binding domain that specifically binds human CD28 comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3),
wherein the HCDR1 of the first antigen-binding domain comprises an amino acid sequence of SEQ ID NO: 12; the HCDR2 of the first antigen-binding domain comprises an amino acid sequence of SEQ ID NO: 6; the HCDR3 of the first antigen-binding domain comprises an amino acid sequence of SEQ ID NO: 14, the LCDR1 of the first antigen-binding domain comprises an amino acid sequence SEQ ID NO: 18, the LCDR2 of the first antigen-binding domain comprises an amino acid sequence SEQ ID NO: 20, and the LCDR3 of the first antigen-binding domain comprises an amino acid sequence SEQ ID NO: 22; and
(b) wherein the second antigen-binding domain that specifically binds human EGFR comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3),
wherein
the HCDR1 of the second antigen-binding domain comprises an amino acid sequence of SEQ ID NO: 4, the HCDR2 of the second antigen-binding domain comprises an amino acid sequence of SEQ ID NO: 6, the HCDR3 of the second antigen-binding domain comprises an amino acid sequence of SEQ ID NO: 8, the LCDR1 of the second antigen-binding domain comprises an amino acid sequence of SEQ ID NOs: 18, the LCDR2 of the second antigen-binding domain comprises an amino acid sequence of SEQ ID NO: 20, and the LCDR3 of the second antigen-binding domain comprises an amino acid sequence of SEQ ID NO: 22.